Abstract Number: 1357 • ACR Convergence 2022
The ANCA-Associated Vasculitis Patient-Reported Outcome (AAV-PRO) Captures Depression and Health-Related Quality of Life More Than Disease Activity and Damage
Background/Purpose: The ANCA-associated vasculitis patient-reported outcome (AAV-PRO) is a new disease-specific PRO developed to capture the impact of having AAV and dealing with its treatment…Abstract Number: 0442 • ACR Convergence 2022
Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based on Physician Specialty, Expertise, and Practice Setting: An International Survey
Background/Purpose: Therapies for ANCA-associated vasculitis (AAV) have evolved over the last 3 decades. In light of new data on plasma exchange (PLEX) and glucocorticoid (GC)…Abstract Number: 0491 • ACR Convergence 2022
Markers of Neutrophil Activation in Patients with ANCA-associated Vasculitis and Large-vessel Vasculitis
Background/Purpose: Neutrophils contribute to the pathogenesis of many autoimmune diseases. The purpose of the study was to assess two markers of neutrophil activation, calprotectin and…Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…Abstract Number: 1574 • ACR Convergence 2022
Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System
Background/Purpose: Vasculitides have been reported as adverse events (AEs) related to a wide variety of medications. We aimed to analyze the vasculitides reported to a…Abstract Number: 0443 • ACR Convergence 2022
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…Abstract Number: 0513 • ACR Convergence 2022
The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Clinical characteristics and outcomes often differ between children and adults diagnosed with the same rheumatic condition; however, such comparative data is limited in ANCA-associated…Abstract Number: 1080 • ACR Convergence 2022
Performance of Risk Prediction Models for Relapse and Severe Infection at the End of 18-month Rituximab Maintenance Therapy in ANCA-associated Vasculitides: Data from the MAINRITSAN Trials
Background/Purpose: Long-term follow-up analysis of the three MAINRITSAN trials confirmed the efficacy of rituximab (RTX) in preventing relapses in ANCA-associated vasculitis (AAV), especially RTX administration…Abstract Number: 1615 • ACR Convergence 2022
Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality
Background/Purpose: The deleterious effect of inflammation combined with glucocorticoid treatment may increase the risk for atherosclerotic events. The aims of this study were to investigate…Abstract Number: 0444 • ACR Convergence 2022
Prevalence of Frailty and Associated Factors in Patients with Vasculitis
Background/Purpose: Frailty is a syndrome characterized by an increased vulnerability to stressors and is associated with disability and early mortality. Frailty may be accelerated in…Abstract Number: 0525 • ACR Convergence 2022
Recovery of Renal Function Among ANCA-Associated Vasculitis Patients with Baseline eGFR ≤20 in the Avacopan ADVOCATE Trial
Background/Purpose: In the 330-patient ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis, in which 81% of patients with ANCA-associated vasculitis had renal involvement,…Abstract Number: 1081 • ACR Convergence 2022
Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection that may affect patients with ANCA vasculitis (AAV). Current guidelines conditionally recommend PJP prophylaxis for patients…Abstract Number: 1688 • ACR Convergence 2022
Biomechanical Phenotype of Circulating Neutrophils Is Altered in ANCA Associated Vasculitis
Background/Purpose: Real Time-Deformability Cytometry (RT-DC) is a novel technique able to identify morpho-rheological characteristics of individual cells such as size, deformability, and elasticity using only…Abstract Number: 0445 • ACR Convergence 2022
Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
Background/Purpose: Several studies have reported that patients with ANCA-associated vasculitis (AAV) are at increased risk of cardiovascular complications from accelerated atherosclerosis with an excess cardiovascular…Abstract Number: 0526 • ACR Convergence 2022
Characteristics and Outcomes of Participants with and Without Diffuse Alveolar Hemorrhage in the Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis (PEXIVAS) Trial
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening manifestation of ANCA-associated vasculitis (AAV). Studies describing patients with DAH in AAV have typically been small…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 19
- Next Page »